J&J’s Comprehensive Approach To Finding A ‘Functional Cure’ For HBV

Capsid assembly modulation, small-interfering RNA, a TLR7 agonist and a DNA-based vaccine are some of the components of the pharma’s strategy for bringing about significant advancement in hepatitis B therapy.